Anti-Microbial Savior BioteQ Co., Ltd.
TTPEX:686445.10
TWD
-1.15
(-2.49%)
ISIN
TW0006864002
Return %
Stock
S&P 500
1Y
-49.46
14.20
3Y
72.17
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Yi Ju Tsai
- Full Time Employees
- 15
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- No. 6, Siwei 3rd Road Kaohsiung City KH Taiwan 802701
- IPO Date
- Dec 29, 2021
- Website
- ams-bioteq.com
- Similar Companies
- Business
- Anti-Microbial Savior BioteQ Co., Ltd. (6864.TWO) develops pharmaceutical products focused on antimicrobial solutions, including new medical dressings, antibacterial drugs, antiviral drugs, and medicinal fungi-derived compounds; its core offerings encompass the SIPSIP Foam wound dressing series, which features hydrophilic, environmentally friendly materials for moist wound healing with anti-adhesion and tissue regeneration properties, alongside the YUAN series of candidate antibiotics such as YUAN-03, which demonstrates near-100% inhibition of SARS-CoV-2 and hCoV-OC43 viruses in vitro, and the small molecule antiviral AMS-2140 targeting emerging viruses and superbugs. The company, founded in 2018 and headquartered in Kaohsiung City, Taiwan, operates primarily in the biotechnology sector with a focus on bioengineering technologies like ExtrO TM for antibiotic resistance solutions; it targets healthcare markets including chronic wound care for diabetes patients, long-term care facilities, and infectious disease treatment, while expanding into agricultural applications via its SeepPlug growing medium for orchids, vegetables, fruits, and high-value crops. Geographically, operations center in Taiwan with international outreach through U.S. FDA and Japanese PMDA approvals for SIPSIP Foam in 2024, enabling entry into the U.S. chronic wound market valued at $5.1 billion, alongside collaborations in Thailand and the U.S. for AMS-2140 trials; recent partnerships include a 2024 distribution deal for its Premium Vitality Drink “Chi” with China’s Vitahouse and a September 2024 agreement with a Japanese healthcare group to expand SIPSIP Foam distribution, complemented by plans for AI-driven drug screening, early licensing with global pharmaceutical firms, and enhanced Japanese market presence via Medical Japan exhibitions for wound care kits and agricultural media.